Explore 3 Stock Ideas & Industry Insights Download Free Report

News

MetLife President Reports Deferred Dividend Reinvestment

Ramy Tadros, President of U.S. Business at MetLife, Inc., filed a statement of changes in beneficial ownership on September 10, 2026, reporting an acquisition of common stock on September 8, 2026.

Shwetambri Chauhan | 10 September 2026

Robinhood Markets Director Sells 1,875 Shares Under 10b5-1 Plan

A Form 4 filed on September 10, 2026 disclosed that Oluwadara Johnson Treseder, a director of Robinhood Markets, Inc. (NASDAQ:HOOD), sold 1,875 shares of Class A Common Stock on September 8, 2026 under a pre-established Rule 10b5-1 trading plan.

Anjali Anand | 10 September 2026

Septerna CMO Receives 275,000 Stock Options

Rajiv Patni, Chief Medical Officer of Septerna, Inc., filed a Form 4 on September 10, 2026, disclosing the acquisition of a stock option covering 275,000 shares of common stock on September 8, 2026.

Anjali Anand | 10 September 2026

Sharplink CFO Officer Shares Withheld for RSU Tax Obligation

Dana Eschenburg Perez, Chief Accounting Officer of Sharplink, Inc. (NASDAQ:SBET), filed a Form 4 on September 10, 2026, reporting a share withholding transaction dated September 9, 2026, related to the vesting and settlement of restricted stock units.

Anjali Anand | 10 September 2026

GlobalFoundries Director Reports RSU Vesting and Share Withholding

A Form 4 filed on September 10, 2026 discloses that Camilla Languille, a director of GlobalFoundries Inc., had 5,235 restricted stock units vest and settle into ordinary shares on September 8, 2026, with 1,571 shares withheld by the issuer for tax obligations.

Anjali Anand | 10 September 2026

Iovance Biotherapeutics CRO Reports RSU Vesting and Tax Withholding

Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), filed a Form 4 on September 10, 2026, disclosing transactions in common stock and restricted stock units dated September 8, 2026.

Aditi Sarkar | 10 September 2026

Iovance Biotherapeutics COO Reports RSU Vesting and Share Withholding

Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, Inc., filed a Form 4 on September 10, 2026, reporting transactions in the company's common stock on September 8, 2026, related to the vesting of restricted stock units.

Anjali Anand | 10 September 2026

Iovance Biotherapeutics Interim CEO Reports RSU Vesting

Frederick G. Vogt, Interim CEO and General Counsel of Iovance Biotherapeutics, Inc., filed a Form 4 on September 10, 2026, reporting transactions in common stock and restricted stock units dated September 8, 2026.

Nitish Kishor | 10 September 2026

Aramark COO Acquires Shares via Dividend Equivalents

Marc A. Bruno, Chief Operating Officer of U.S. Food & Facilities at Aramark, filed a Form 4 on September 10, 2026, reporting the acquisition of 282.012 shares of Aramark common stock at no cost on September 9, 2026.

Anjali Anand | 10 September 2026

Aramark CFO Receives Dividend Equivalent Rights on Equity Awards

James J. Tarangelo, Executive Vice President and CFO of Aramark (NYSE:ARMK), filed a Form 4 on September 10, 2026, reporting the acquisition of dividend equivalent rights on restricted stock units and performance stock units on September 9, 2026.

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…